Quantcast

Hikma launches Dihydroergotamine Mesylate Injection, USP

Hikma Pharmaceuticals PLC (rated Ba1 Moody’s / BB+ S&P, both stable) has announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), has launched Dihydroergotamine Mesylate Injection, USP, 1mg/mL.

West-Ward’s Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
According to IMS Health, US sales of Dihydroergotamine Mesylate Injection, USP were approximately $34.8 million in the 12 months ending October 2017.
Riad Mechlaoui, Chief Executive Officer of Injectables said, “We are pleased to be adding Dihydroergotamine Mesylate Injection, USP to our Injectables portfolio in the US. We have a large portfolio of products and a pipeline of differentiated products to support future growth.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.